Clinical trials: Hematological Neoplasm
Myeloid Hematological Malignancies
Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies
In this study, the investigators will use busulfan and cyclophosphamide (BuCy) backbone with the addition of fludarabine as the preparative Stem Cell Transplant (SCT) regimen.
- Trial name
- UCAML (NCT01247701)
- Testing
- Busulfan, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Baylor College of Medicine
Chronic Myeloproliferative Disorders
Imatinib Mesylate in Treating Patients With Myelofibrosis
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of imatinib mesylate and how well it works in…
- Trial name
- NCT00245128
- Testing
- imatinib mesylate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- OHSU Knight Cancer Institute
Advanced Cancer
Primary Palliative Care for Patients With Advanced Hematologic Malignancies
This study seeks to develop and pilot-test an oncology nurse-led care management intervention to meet the primary palliative care needs of patients with advanced hematologic malignancies.
- Trial name
- NCT02992171
- Testing
- care management by oncology nurses
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Pittsburgh
Hematological Disease, Immune Deficiencies
URMC Related Haplo-identical Donor BMT
This study will be a single-center treatment protocol, designed to validate the process of related donor haploidentical-SCT at the Wilmot Cancer Institute Blood and Marrow Transplant Unit.
- Conditions
- Hematological Disease, Immune Deficiencies, Solid Tumors, Myelofibrosis
- Trial name
- HaploOnly (NCT02660281)
- Testing
- Total Body Irradiation 1200 cGy, Fludarabine, Pre-Stem Cell Infusion Cyclophosphamide
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of Rochester
Cytomegalovirus Infections, Haematological Malignancy
Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient
This study consists of two parts: 1) Part 1, a retrospective part on 250 consecutive patients following allogeneic haematopoietic stem cell transplant (allo-HSCT) at the Royal Melbourne Hospital from 2012 to 2017, inclusive, and…
- Conditions
- Cytomegalovirus Infections, Haematological Malignancy, Organ or Tissue Transplant; Complications, Immune Suppression
- Trial name
- CReSCT (NCT03806764)
- Testing
- Blood sampling
- Where
- Australia
- Volunteers
- 370 people
- Sponsor
- Melbourne Health
Gynecologic Cancer
Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy
Can intravenous iron lower the rate of blood transfusion in gynecologic cancer patients receiving platinum based chemotherapy than oral iron?
- Trial name
- NCT01435200
- Testing
- Intravenous iron
- Where
- Thailand
- Volunteers
- 64 people
- Sponsor
- Chulalongkorn University
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia
- Trial name
- Orca-T (NCT05316701)
- Testing
- Orca-T, Standard-of-Care
- Where
- 19 sites in United States
- Volunteers
- 187 people
- Sponsor
- Orca Biosystems, Inc.
Relapsed/Refractory Hematological Malignancies
A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies
This study is an open-label, dose-escalation and efficacy-expansion Phase I clinical trial to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary antitumor activity of QLS2313 as a monotherapy in…
- Trial name
- NCT07294300
- Testing
- QLS2313
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hematopoietic/Lymphoid Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Nurse Practitioner Hospice Program for Patients With Terminal Metastatic Cancer and Their Families or Caregivers
RATIONALE: Gathering information about patients with terminal metastatic cancer may help doctors learn more about the effectiveness of a nurse practitioner hospice program.
- Trial name
- NCT00896792
- Testing
- counseling intervention, questionnaire administration, survey administration
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD
The purpose of this study is to test the effectiveness and safety of adding cyclophosphamide or lenalidomide to the VD combination in the treatment of patients with multiple myeloma that have achieved a stable response after 4…
- Trial name
- SEQUENTIAL (NCT00908232)
- Testing
- Cyclophosphamide, Bortezomib, Dexamethasone
- Where
- 42 sites in France, Germany and 8 more
- Volunteers
- 163 people
- Sponsor
- Janssen-Cilag International NV
Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
The primary aim of this protocol is to evaluate if the one-year survival is significantly improved in the group of patients who receive a T-cell replete haploidentical donor hematopoietic cell transplant (HCT) with a novel…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia, Juvenile Myelomonocytic Leukemia
- Trial name
- NCT01621477
- Testing
- clofarabine, cytarabine, busulfan
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- St. Jude Children's Research Hospital
Solid Tumor and Hematologic Malignancies
MEK162 for Patients With RAS/RAF/MEK Activated Tumors
The purpose of this signal seeking study is to determine whether treatment with MEK162 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study
- Trial name
- SIGNATURE (NCT01885195)
- Testing
- MEK162
- Where
- 68 sites in United States
- Volunteers
- 110 people
- Sponsor
- Pfizer
B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma
- Trial name
- NCT00010192
- Testing
- rituximab, aldesleukin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia.
1. To evaluate expression levels of CD135 2. To assess the frequency of FLT3 gene mutations (ITD) 3. association between FLT3-ITD mutation and CD135 expression and their correlation with hematological, immunophenotypic,and…
- Trial name
- NCT05383014
- Volunteers
- 82 people
- Sponsor
- Assiut University
Blood Cancer
Predictive Markers of Response and Toxicity in Patients With a Haematological Malignancy Treated With Immunotherapy.
Immunotherapies have substantially improved the prognosis of patients with haematological malignancies. While clinical trial data suggest durable complete response rates, markers associated with non-response to treatment are…
- Trial name
- PRONOSTIM (NCT05450367)
- Testing
- Data collection
- Where
- France
- Volunteers
- 249 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Constipation
Ultrafast MRI Imaging to Exclude Constipation
In haematological malignancy and in immunocompromised patients, constipation is a common symptom caused by a number of factors during treatment.
- Trial name
- FIESTA (NCT02658201)
- Testing
- MRI
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- Sheffield Children's NHS Foundation Trust
Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)-related cancers.
- Conditions
- Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection, Kaposi Sarcoma
- Trial name
- NCT05663502
- Testing
- Biospecimen Collection
- Where
- 8 sites in United States
- Volunteers
- 200 people
- Sponsor
- AIDS Malignancy Consortium
Cancer
Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies
This is a two-part study in subjects with hematologic malignancies designed to find the maximum tolerated dose (MTD) of GSK690693 (Part 1).
- Trial name
- NCT00666081
- Testing
- GSK690693
- Sponsor
- GlaxoSmithKline
Neutropenia, Fever
Granulocyte Transfusions in Hematological Patients With Febrile Neutropenia
The investigators retrospectively evaluated the efficacy of granulocyte transfusions as adjunctive treatment for severe infections in neutropenic fever unresponsive to antimicrobial therapy in hematological patients.
- Conditions
- Neutropenia, Fever, Bacterial Infection, Fungal Infection
- Trial name
- NCT02544230
- Where
- Italy
- Volunteers
- 101 people
- Sponsor
- Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne
Hematological Malignancies
Study of AZD9829 in CD123+ Hematological Malignancies
This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.
- Trial name
- NCT06179511
- Testing
- AZD9829
- Where
- 22 sites in United States, Australia and 8 more
- Volunteers
- 56 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.